10607 results for 'myelin antibody'

Quick Facts About NarnatumabWhat is Narnatumab?Narnatumab is a monoclonal antibody targeting CD47, a key immune checkpoint that helps cancer cells evade destruction by the immune system.

Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor

PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a r

Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses

Quick Facts About TrastuzumabWhat is Trastuzumab?Trastuzumab is a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It specifically targets the HER2 protein, re

Quick Facts About VixarelimabWhat is Vixarelimab?Vixarelimab is an investigational monoclonal antibody developed to target oncostatin M receptor beta (OSMRβ), a key pathway involved in p

What You Need to Know About InebilizumabWhat is Inebilizumab?Inebilizumab is a humanized monoclonal antibody that targets CD19, a protein expressed on B cells, to treat autoimmune diseas

Quick Facts About GlenzocimabWhat is Glenzocimab?Glenzocimab is an innovative monoclonal antibody designed to reduce the risk of ischemic stroke by selectively targeting platelet glycopr

A macrophage does not decide to eat; it counts votes. Every particle it touches carries a mixture of pro-phagocytic and inhibitory ligands, and engulfment follows only when the activating tally clear

Quick Facts About CanakinumabWhat is Canakinumab?Canakinumab is a human monoclonal antibody that targets interleukin-1 beta (IL-1β), reducing inflammation associated with various disease

Quick Info Section: Key Facts About PlozalizumabWhat is Plozalizumab?Plozalizumab is an investigational monoclonal antibody that targets CD47, a key immune checkpoint in cancer cells. By

The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.

The year 2026 has brought an unsettling spotlight onto an old adversary: Hantavirus. What began as isolated cases has rapidly escalated into a multi-country surge, leaving scientists and public healt

CD25, a key molecule in immune regulation, is integral to the function of activated lymphocytes and regulatory T cells. It's central in mediating immune responses, with implications in autoimmune

Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression

Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik

Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary

Introduction Discover the multifaceted role of CD33, a critical player in immune function and disease, shaping our approach to treating cancers and neurodegenerative conditions

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b